Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06200389 |
Other study ID # |
MA-VVC-EI-001 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 1, 2024 |
Est. completion date |
July 1, 2025 |
Study information
Verified date |
October 2023 |
Source |
Beijing Tsinghua Chang Gung Hospital |
Contact |
Qinping Liao |
Phone |
+86-13701124527 |
Email |
13701124527[@]163.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
We has proposed to conduct a national epidemiological study on the pathogenic strains and
high risk factors of Vulvovaginal Candidiasis in China , and conduct drug resistance
analysis.
Description:
Vulvovaginal Candidiasis is a mucosal infectious disease, which rarely occurs fatal
infection, but has high recurrence rate. Vulvovaginal Candidiasis often leads to decreased
life quality and serious economic burden. However, we known little about the pathogenesis of
Vulvovaginal Candidiasis. So better diagnosis and treatment methods are needed to decrease
the impact on women's health.
In 2017, the national Vulvovaginal Candidiasis epidemiological survey led by Professor Liao
showed that 543 strains of fungi were isolated from different patients from 12 hospitals in
10 cities in China, of which Recurrence Vulvovaginal Candidiasis strains accounted for 15.7%.
The most common pathogenic strain was Candida albicans (460 species, 84.71%), and the most
common non-albicans was Candida glabra (47 species, 8.66%). In addition, 92 isolates (20.4%)
belonged to the new branch endemic to North China. Vaginal symptoms of Vulvovaginal
Candidiasis caused by non-albicans are usually milder compared to Vulvovaginal Candidiasis
caused by Candida albicans. However, inherent resistance to azoles, as well as acquired
resistance mechanisms, can complicate the treatment of non-albicans and often requires a
long-term antifungal treatment or other treatments to clear non-albicans.
Given that the resistance rate of different types of candida to antifungal drugs changes over
time, common antifungal drugs have selective induction of resistance to fungi, and fungi have
cross-induction of resistance to antifungal drugs, it is very important to evaluate the
distribution and resistance of Candida species in a long-term . Accurate and effective
acquisition of candida epidemiological data to understand the recent status and drug
resistance of Candida infection can effectively guide clinical treatment to improve the
therapy, and play a very important role in clinical diagnosis and treatment. Therefore,
Professor Liao has proposed to conduct a national epidemiological study on the pathogenic
strains and high risk factors of Vulvovaginal Candidiasis in China once again, and conduct
drug resistance analysis, in order to guide clinicians to better Vulvovaginal Candidiasis
treatment.